Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN)

Core Insights - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is recognized as a promising healthcare stock with significant upside potential, despite a recent price target reduction from $90 to $80 by Cantor Fitzgerald analyst Olivia Brayer [1] - J.P. Morgan analyst Jessica Fye maintains a Buy rating with a higher price target of $119, indicating strong confidence in the stock [2] - BMO Capital analyst Kostas Biliouris also supports a Buy rating with a price target of $115, highlighting the company's growth prospects following positive data presentations [3] Company Developments - BioMarin presented new data from 14 studies at the ASBMR Annual Meeting, showcasing the effectiveness of VOXZOGO® (vosoritide) in improving spinal morphology in young children [3] - The potential expansion of Palynziq into the adolescent market is identified as a key growth driver, which could enhance BioMarin's market share [4] - The company focuses on developing therapies for serious medical conditions and rare diseases, with a product pipeline that includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [4]